

Regulation of Monocyte Functional Heterogeneity by *miR-146a* and Relb

Martin Etzrodt,^{1,9} Virna Cortez-Retamozo,^{1,9} Andita Newton,¹ Jimmy Zhao,³ Aylwin Ng,² Moritz Wildgruber,¹ Pedro Romero,⁴ Thomas Wurdinger,⁵ Ramnik Xavier,² Frederic Geissmann,⁶ Etienne Meylan,⁷ Matthias Nahrendorf,¹ Filip K. Swirski,¹ David Baltimore,³ Ralph Weissleder,^{1,8} and Mikael J. Pittet^{1,*}

¹Center for Systems Biology

²Center for Computational and Integrative Biology and Gastrointestinal Unit

Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

³Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA

⁴Ludwig Center for Cancer Research, CH-1005 Lausanne, Switzerland

⁵Cancer Center Amsterdam, VU University Medical Center, Amsterdam 1080, The Netherlands

⁶Centre for Molecular and Cellular Biology of Inflammation, King's College London, SE1 1UL London, UK

⁷Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland

⁸Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA

⁹These authors contributed equally to this work

*Correspondence: mpittet@mgh.harvard.edu

DOI 10.1016/j.celrep.2012.02.009

SUMMARY

Monocytes serve as a central defense system against infection and injury but can also promote pathological inflammatory responses. Considering the evidence that monocytes exist in at least two subsets committed to divergent functions, we investigated whether distinct factors regulate the balance between monocyte subset responses in vivo. We identified a microRNA (miRNA), *miR-146a*, which is differentially regulated both in mouse (Ly-6C^{hi}/Ly-6C^{lo}) and human (CD14^{hi}/CD14^{lo}CD16⁺) monocyte subsets. The single miRNA controlled the amplitude of the Ly-6C^{hi} monocyte response during inflammatory challenge whereas it did not affect Ly-6C^{lo} cells. *miR-146a*-mediated regulation was cell-intrinsic and depended on Relb, a member of the noncanonical NF- κ B/Rel family, which we identified as a direct *miR-146a* target. These observations not only provide mechanistic insights into the molecular events that regulate responses mediated by committed monocyte precursor populations but also identify targets for manipulating Ly-6C^{hi} monocyte responses while sparing Ly-6C^{lo} monocyte activity.

INTRODUCTION

Monocytes are the circulating precursors of several types of macrophages and dendritic cells (Geissmann et al., 2010). They confer protection of injured or infected tissue but also propagate chronic diseases (Auffray et al., 2009; Qian and Pollard, 2010; Shi and Pamer, 2011). At least two CD11b⁺ CD115⁺ monocyte populations exist in mice: 1), Ly-6C^{hi} (Gr-1⁺ CCR2⁺

CX3CR1^{lo}) cells respond to proinflammatory cues such as CCL2 (or MCP-1), migrate to inflamed sites and draining lymph nodes, and can differentiate into antigen-presenting dendritic cells (Cheong et al., 2010) and orchestrate inflammatory functions (Swirski et al., 2007; Tacke et al., 2007); and 2), Ly-6C^{lo} (Gr-1⁺ CCR2⁺ CX3CR1^{hi}) cells patrol the resting endothelium (Auffray et al., 2007), can be recruited to tissue after the onset of inflammation, and participate in granulation tissue formation (Nahrendorf et al., 2007). Ly-6C^{hi} monocytes recirculate into the bone marrow where they can convert into Ly-6C^{lo} monocytes (Varol et al., 2007). Monocyte heterogeneity is conserved at least in part in mice and humans: mouse Ly-6C^{hi} monocytes share phenotypic and functional features with human CD14^{hi} cells, whereas mouse Ly-6C^{lo} monocytes resemble human CD14^{lo} CD16⁺ cells (Cros et al., 2010).

Infection (Shi and Pamer, 2011), injury (Nahrendorf et al., 2007), atherosclerosis (Swirski et al., 2007; Tacke et al., 2007), cancer (Movahedi et al., 2010), and other pathophysiological conditions alter monocyte subset ratios. Changes of ratios can occur rapidly (e.g., hours after pathogenic infection), be long lasting (e.g., in chronic inflammatory disorders), and typically result in the selective amplification of proinflammatory Ly-6C^{hi} cells. Human studies have underscored the relevance of studying monocyte subsets because an imbalance in their relative proportion is linked to several diseases (Ziegler-Heitbrock, 2007). The factors that regulate the balance between monocyte subset responses are largely unknown. The identification of such factors is potentially useful as it may offer new vantage points for tailoring immune responses to a desired phenotype.

RESULTS

Mir-146a Is a Candidate Regulator of Monocyte Functional Heterogeneity

MicroRNAs (miRNAs) regulate target genes at the posttranscriptional level and can control distinct functional properties in cell




Figure 1. Mouse Monocyte Subsets Show Distinct *miR-146a* and Inflammatory Profiles

(A) Microarray analysis of miRNA expression in Ly-6C^{hi} versus Ly-6C^{lo} splenic monocytes. Genes with >2-fold change among subsets and $p < 0.05$ are highlighted ($n = 4$ biological replicates).

(B) Relative *miR-146a* expression in various hematopoietic cell types. Expression is relative to splenic Ly-6C^{hi} monocytes ($n = 3$ animals for all cell populations except for spleen monocytes, $n = 7$).

(C) Analysis of differentially expressed genes in Ly-6C^{hi} versus Ly-6C^{lo} blood monocytes using the Panther database of biological functional categories.

(D) Quantification of TNF α , IL-6, IL-1b and IL-10 production by splenic monocytes 8 hr after LPS challenge ($n = 3$ –4).

(E) p65 immunofluorescence staining in sorted monocyte subsets. Ly-6C^{hi} monocytes stimulated for 30' with TNF α prior to fixation served as a positive control for effective nuclear translocation. Scale bar represents 10 μ m.

(F) Time-course analysis of *miR-146a* levels after LPS challenge. Expression is relative to Ly-6C^{hi} monocytes at time 0 hr ($n = 2$). Data are presented as mean \pm SEM (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, Student's t test).

See also Figure S1.

types that are closely related ontogenically. miRNAs are known to regulate the development and function of various immune cell types (O'Connell et al., 2010) but have to date not been investigated in the context of monocyte heterogeneity. Here we compared the expression levels of 380 miRNAs in sorted monocyte subsets (Figure S1A) and defined significant genes as those with at least 2-fold differential expression and a $p < 0.05$ (Student's t test). The approach identified nine miRNAs, which were highly expressed either in Ly-6C^{hi} (*miR-20b*, -135a, -424, -702) or in Ly-6C^{lo} monocytes (*miR-146a*, -150, -155, -342, -29b) (Figure 1A).

Independent assays indicated ~ 2 orders of magnitude higher expression of *miR-146a* in Ly-6C^{lo} monocytes when compared to hematopoietic stem cells (HSC), granulocyte/macrophage progenitors (GMP), macrophage/dendritic cell progenitors (MDP), and Ly-6C^{hi} monocytes in steady-state (Figure 1B). Thus, monocytes express *miR-146a* only at a late maturation stage and selectively in the Ly-6C^{lo} subset. Steady-state dendritic cell populations expressed *miR-146a* at intermediate levels (Figure 1B).

miRNAs and their respective target genes are often mutually exclusively expressed in a given tissue (Farh et al., 2005). In keeping with previous observations that *miR-146a* suppresses NF- κ B-dependent inflammatory pathways (Taganov et al., 2006), we confirmed with two independent genome-wide profiling methods that blood *miR-146a*^{lo} Ly-6C^{hi} monocytes showed increased inflammatory signatures (Swirski et al., 2009) and expressed components of the NF- κ B signaling cascade at higher levels than their *miR-146a*^{hi} Ly-6C^{lo} counterparts (Figures 1C and S1B). Also, splenic and blood *miR-146a*^{lo} Ly-6C^{hi} monocytes stimulated with lipopolysaccharide (LPS) produced more TNF α , IL-6, and IL-1b inflammatory cytokines than *miR-146a*^{hi} Ly-6C^{lo} cells (Figures 1D and S1C).

The elevated *miR-146a* expression in Ly-6C^{lo} cells and the inflammatory profile of Ly-6C^{hi} cells reported above were likely not due to a premature activation artifact induced by the isolation procedure because I κ B α protein levels were similar in both monocyte subsets ex vivo (Figure S1D) and NF- κ B subunit p65 only became detectable in the nucleus of Ly-6C^{hi} cells upon in vitro challenge (Figure 1E). The cause for constitutive (NF- κ B

-independent) *miR-146a* expression in Ly-6C^{lo} cells will require additional investigation.

Differential *Mir-146a* Expression in Monocytes in Steady State and Inflammation

We addressed the regulation of *miR-146a* expression in monocyte subsets upon ex vivo challenge with either LPS, heat killed *Listeria monocytogenes* (HKLM) or TNF α . *miR-146a* was induced only in Ly-6C^{hi} monocytes, in response to all stimuli, and reached levels matching those in Ly-6C^{lo} cells (Figure S1E). In vivo LPS challenge studies confirmed the in vitro findings (Figure S1F). *miR-146a* expression in Ly-6C^{hi} cells increased within 4 hr after LPS challenge and reached levels equivalent to those found in Ly-6C^{lo} cells after 16 hr (Figure 1F). Thus, *miR-146a* expression is constitutive in Ly-6C^{lo} monocytes and inducible in Ly-6C^{hi} monocytes. LPS-stimulated Ly-6C^{hi} monocytes were CD11c⁺ MHC II^{high} (Ly-6C^{hi}) and thus distinct from Ly-6C^{lo} monocytes (Figure S1G).

Mir-146a Controls Monocyte Subset Ratios during Inflammatory Reactions

To investigate the role of *miR-146a* in monocytes in vivo, we generated mice in which *miR-146a* expression was either up- or downregulated experimentally. To constitutively overexpress *miR-146a* we reconstituted mice with HSC transduced to coexpress EGFP and *miR-146a* (Figures S2A and S2B). *miR-146a* overexpression did not alter monocyte numbers or subset ratios in steady state (Figure S2C); however, upon *Listeria monocytogenes* (*Lm*) infection (Shi and Pamer, 2011), it prevented the unfolding of a full-fledged TNF α -producing Ly-6C^{hi} monocyte response (Figures 2A and 2B).

To suppress *miR-146a* expression in vivo we used two independent approaches. The first one involved systemic delivery of anti-miRNA locked nucleic acid (LNA) formulations (Figures S2D and S2E). LNA treatment did not alter monocyte subset ratios in steady state (Figure S2F) but it increased the number of TNF α -producing Ly-6C^{hi} monocytes at *Lm* infected sites (Figures 2C and 2D).

The second approach to suppress *miR-146a* expression used recently described mice with targeted deletion of the *miR-146a* gene (Boldin et al., 2011) (Figure S2G). *miR-146a*^{-/-} mice contained both monocyte subsets thus Ly-6C^{hi} \rightarrow Ly-6C^{lo} monocyte conversion should not require *miR-146a*. Also, *miR-146a* knock-down did neither alter the ratio (Figure 2E) nor the phenotype (Figure S2H) of monocyte subsets in 8-week-old mice. To compare *miR-146a*^{-/-} and wild-type monocyte responses as they developed in the same environments, we reconstituted wild-type (CD45.1) mice with equal numbers of *miR-146a*^{-/-} (CD45.2) and wild-type (EGFP⁺ CD45.2) cells (Figure S2I). The absence of *miR-146a* strongly amplified TNF α -producing Ly-6C^{hi} peritoneal monocytes in response to LPS challenge (Figures 2F and 2G). Ly-6C^{hi} monocytes mediate immune defense in early phase of *Lm* infection (Shi and Pamer, 2011). Accordingly, *Lm*-infected *miR-146a*^{-/-} mice contained reduced numbers of viable *Lm* 24 hr postinfection when compared to *Lm*-infected wild-type mice (Figure 2H). Amplification of the Ly-6C^{hi} monocyte response in absence of *miR-146a* was confirmed in a model of sterile peritonitis induced by thioglycollate (Figure 2I).

Cell-Intrinsic *Mir-146a*-Mediated Regulation of the Ly-6C^{hi} Monocyte Response

The experiments above involved indiscriminate alteration of *miR-146a* expression in all hematopoietic cells. We reasoned that injection of *miR-146a*^{-/-} GMP into wild-type mice would permit to track *miR-146a*^{-/-} monocytes in a wild-type environment because *miR-146a* is only upregulated upon progenitor cell maturation. Specifically, we coadministered equal numbers of *miR-146a*^{-/-} (CD45.2 EGFP⁺) and wild-type (CD45.2 EGFP⁺) GMP into nonirradiated wild-type (CD45.1) mice, which were subsequently challenged with LPS intraperitoneally (i.p.) (Figure S2J). Wild-type and *miR-146a*^{-/-} hematopoietic progenitor cells show comparable clonogenic potential (Boldin et al., 2011; Figure S2K) and the transferred cells' progeny contained monocytes and neutrophils, as expected. *miR-146a*^{-/-} monocytes recruited to the peritoneal cavity outnumbered their wild-type counterparts (Figures 2J and 2K) and were Ly-6C^{hi} (Figure 2L); in marked contrast, *miR-146a*^{-/-} neutrophils—that do not upregulate *miR-146a* in vivo—mounted a response that was similar to their wild-type counterparts (Figure 2K). Thus *miR-146a* should regulate Ly-6C^{hi} monocytes at least in part in a cell-intrinsic manner.

Mir-146a Controls Ly-6C^{hi} Monocyte Proliferation and Trafficking in Inflammatory Conditions

In contrast to previous descriptions for other cell types (Nahid et al., 2009; Boldin et al., 2011), including macrophages (Figure S3A), the absence of *miR-146a* did not detectably alter inflammatory cytokine production by Ly-6C^{hi} and Ly-6C^{lo} monocytes on a per-cell basis (Figures 3A and 3B). However, LPS challenge increased the percentage of *miR-146a*^{-/-} Ly-6C^{hi} monocytes undergoing cell division in bone marrow (Figures 3C and 3D) and to a lower extent in the spleen and peritoneal cavity (Figure 3D). The absence of *miR-146a* did not affect proliferation of Ly-6C^{lo} monocytes (Figure S3B). Cocultures of *miR-146a*^{-/-} and wild-type cells also indicated a proliferative advantage for bone marrow *miR-146a*^{-/-} Ly-6C^{hi} monocytes (Figures S3C and S3D).

In addition, coinjection of bone marrow *miR-146a*^{-/-} (EGFP⁺ CD45.2) and control (EGFP⁺ CD45.2) Ly-6C^{hi} monocytes into LPS-treated wild-type (CD45.1) mice showed higher accumulation of *miR-146a*^{-/-} cells at the site of inflammation within only 6 hr (Figure 3E). The chemokine CCL2 controls Ly-6C^{hi} monocyte migration to inflamed sites (Shi and Pamer, 2011). Interestingly, *miR-146a*^{-/-} blood Ly-6C^{hi}—but not Ly-6C^{lo}—monocytes expressed the cognate receptor CCR2 at higher levels than their wild-type counterparts (Figures 3F and S3E) and migrated more efficiently toward a CCL2 gradient in vitro (Figure 3G).

These observations indicate that *miR-146a* controls the expansion of Ly-6C^{hi} monocytes during acute inflammatory conditions in part through elevated proliferation of Ly-6C^{hi} monocytes—predominantly in the bone marrow—and increased trafficking to inflamed sites.

Relb Is a *Mir-146a* Target

We aimed to find endogenous *miR-146a* target genes that contribute to altering the monocyte response. The screening approach, which compared the expression profiles of *miR-146a*-predicted target genes in Ly-6C^{hi} and Ly-6C^{lo} monocytes either




Figure 2. Effects of Ectopic *miR-146a* Expression or *miR-146a* Silencing on the Ly-6C^{hi} Monocyte Response

(A) Monocyte counts in spleen of mice reconstituted with *miR-146a*-expressing (*miR-146a*^{hi}) or control (*miR-146a*^{norm}) vector and challenged with *Lm* (n = 3–5 from two independent experiments).

(B) Number of TNFα-producing monocytes after ex vivo re-stimulation (same mice as in A).

(C) Monocyte counts in spleen of mice that received either anti-*miR-146a* LNA or PBS and were challenged with live *Lm* for 24 hr (n = 3).

(D) Number of TNFα-producing monocytes after LNA treatment (same mice as in C).

(E) Ly-6C^{hi}/Ly-6C^{lo} monocyte ratios in blood of wild-type (1.03 ± 0.03) and *miR-146a*^{-/-} (1.05 ± 0.04) mice in steady-state (mean ± SEM).

(F) Fold increase of Ly-6C^{hi} and Ly-6C^{lo} *miR-146a*^{-/-} monocytes in peritoneal cavity compared to their wild-type counterparts in bone marrow chimeras 4 days after peritoneal LPS injection (n = 4 from two independent experiments).

(G) Number of TNFα-producing wild-type or *miR-146a*^{-/-} monocytes (same mice as in F).

(H) Colony forming unit (CFU) assay to quantify viable *Lm* from the spleen of wild-type (n = 6) and *miR-146a*^{-/-} (n = 5) mice 24 hr after infection.

(I) Fold increase of Ly-6C^{hi} and Ly-6C^{lo} *miR-146a*^{-/-} monocytes compared to their wild-type counterparts in bone marrow chimeras 24 hr after peritoneal thioglycollate injection (n = 3).

(J) Tracking of EGFP⁺ wild-type and EGFP⁻ *miR-146a*^{-/-} CD45.2 GMP progeny. Right dot plot shows CD45.2 Lin⁻ CD11b⁺ CD115⁺ donor GMP-derived monocyte (representative of four independent experiments).

(K) Fold increase of *miR-146a*^{-/-} neutrophils and monocytes (GMP donor-derived) compared to their wild-type counterparts in the peritoneal cavity 4 days after LPS challenge (n = 4 from two independent experiments).

(L) Ly-6C expression by donor GMP-derived monocytes (same mice as in K). Data are presented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, Student's t test). See also Figure S2.

at 2 hr or 8 hr after *Lm* challenge (Figure S4A and Supplemental Information), identified the transcription factor *Relb* (Figure 4A). Experimental evidence also indicates that *Relb* is a *miR-146a*

target. First, ectopic *miR-146a* expression in resting Ly-6C^{hi} monocytes in vivo reduced *Relb* transcript levels (Figure 4B). Second, NIH 3T3 cells transfected with a luciferase reporter




Figure 3. Altered Proliferation and Trafficking of *miR-146a*^{-/-} Ly-6C^{hi} Monocytes during Inflammation

(A) Cytokine production of sorted wild-type and *miR-146a*^{-/-} monocyte subsets after in vitro LPS stimulation. Cytokine production is expressed per cell (n = 2–3). (B) Time course TNFα production by Ly-6C^{hi} monocytes upon LPS challenge in vitro (n = 2). (C) Gating strategy for DAPI staining of bone marrow Ly-6C^{hi} monocytes. Histograms show data for LPS stimulated wild-type or *miR-146a*^{-/-} animals. (D) Quantification of cell cycle status in wild-type and *miR-146a*^{-/-} animals in steady state (n = 2) or after 4 consecutive days of LPS injection i.p. (n = 4) in bone marrow, spleen and peritoneal cavity. (E) Number of donor wild-type and *miR-146a*^{-/-} EGFP⁺ CD45.2 Ly-6C^{hi} monocytes retrieved in the peritoneal cavity 6 hr after transfer into LPS-treated CD45.1 recipient mice (n = 4). (F) Flow cytometry-based cell surface CCR2 mean-fluorescence intensity (MFI) in wild-type and *miR-146a*^{-/-} blood monocytes (n = 8). (G) In vitro chemotactic activity of wild-type (EGFP⁺) and *miR-146a*^{-/-} (EGFP⁺) Ly-6C^{hi} monocytes toward MCP-1 (n = 4). Data are presented as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, Student's t test). See also Figure S3.

plasmid expressing *Relb* 3' UTR (ENSMUST00000049912) containing a potential *miR-146a* binding sequence showed reduced luciferase activity upon *miR-146a* overexpression. The phenotype was rescued by mutating the seed sequence (Figure 4C). Third, immunofluorescence microscopy with a validated anti-Relb Ab (Figure S4B) showed efficient nuclear translocation of Relb protein at 30 min after LPS challenge in both wild-type and *miR-146a*^{-/-} Ly-6C^{hi} monocytes; however at 6 hr cytoplasmic Relb levels were recovered more prominently in the *miR-146a*^{-/-} cells (Figure 4D). Fourth, flow cytometry analysis confirmed that Relb protein levels remained higher in *miR-146a*^{-/-} Ly-6C^{hi} monocytes upon LPS challenge (Figure 4E).

Modulation of Relb Expression Affects the Ly-6C^{hi} Monocyte Response

To investigate whether modulation of Relb affects the monocyte response, we generated both Relb^{hi} EGFP^{hi} CD45.1 HSC (that expressed Relb from a cDNA sequence that could not be regulated by *miR-146a*) and control Relb^{norm} EGFP^{hi} CD45.2 HSC, which were adoptively transferred at a 1:1 ratio into LPS-treated CD45.1/2 recipient animals (Figure S4C). Relb overexpression did not alter HSC expansion (Figure S4D) but amplified the monocyte response in vivo (Figure 4F) and thus

recapitulated the phenotype observed for *miR-146a*^{-/-} Ly-6C^{hi} monocytes.

We also injected LPS-treated CD45.1 mice either with *miR-146a*^{-/-} shRelb EGFP^{hi} HSC (that expressed a *miR30*-hairpin based shRNA to silence *Relb* to the levels found in challenged wild-type monocytes) or with *miR-146a*^{-/-} EGFP^{hi} HSC (that expressed a control EGFP vector) (Figures 4G and S4E). *Relb* silencing did not alter HSC expansion (Figure S4F) but decreased *miR-146a*^{-/-} Ly-6C^{hi} monocyte responses in vivo (Figure 4H). These data indicate that *miR-146a* can control Ly-6C^{hi} monocyte fate in response to acute inflammatory challenge via *Relb* targeting.

miR-146a and Relb Expression in Human Monocytes

The human *Relb* 3'UTR contains a binding site for the alternative processing isoform *miR-146a-3p* (*miR-146a*^{*}) instead of the "canonical" *miR-146a-5p* isoform (*miR-146a*) (transcript ENST00000221452, Figure S4G). *miR-146a*, and most notably *miR-146a*^{*}, were detected at higher levels in human CD16⁺ (CD14^{lo}) monocytes than in their CD14⁺(CD16⁻) counterparts ex vivo (Figures 4I, S4H, and S4I), and were selectively induced in CD14⁺(CD16⁻) monocytes 6 hr post-LPS challenge (Figures 4J, S4J, and S4K). *miR-146a*^{*} was also detected in mouse




Figure 4. *Relb* Is a *miR-146a* Target in Monocytes

(A) Relative *Relb* mRNA expression in monocytes subsets recruited to the peritoneal cavity at 2 hr (early) and 8 hr (late) postinflammatory challenge. Data are normalized to *Ly-6C^{hi}* monocytes at 2 hr ($n = 3$).

(B) Relative *Relb* mRNA expression in steady-state *Ly-6C^{hi}* monocytes that overexpress *miR-146a* (*miR-146a^{hi}*) or not (*miR-146a^{norm}*) ($n = 3$).

(C) Luciferase reporter assay for *miR-146a*-dependent regulation of *Relb* 3' UTR. Luciferase activity was measured in NIH 3T3 cells transfected with control empty vector, *Relb* 3' UTR or a mutated version of the *Relb* 3' UTR.

(D) Immunofluorescence staining of *Relb* protein in wild-type or *miR-146a^{-/-}* *Ly-6C^{hi}* monocytes at 0, 0.5 and 6 hr after LPS challenge. (Images are representative of $n = 7$ –21 cells analyzed per condition). Scale bar represents 10 μ m. Quantification shows cytoplasmic versus nuclear fluorescence signal ratios.

(E) Flow cytometry evaluation of intracellular *Relb* protein expression levels in wild-type or *miR-146a^{-/-}* *Ly-6C^{hi}* blood monocytes in steady-state or 6 hr after LPS challenge ($n = 5$).

(F) Tracking of EGFP⁺ monocytes reconstituted with a *Relb*-overexpressing (*Relb^{hi}*) or control (*Relb^{norm}*) vector in the peritoneal cavity 7 days after LPS challenge. Gating shows a representative result of the two competing monocyte populations ($n = 4$ animals per group).

(G) shRNA-mediated knockdown in EGFP⁺ cells measured by real-time PCR in *miR-146a^{-/-}* *Ly-6C^{hi}* monocytes ($n = 3$).

(H) Accumulation in the peritoneal cavity of EGFP⁺ *miR-146a^{-/-}* monocytes transfected either with a *shRelb* or control construct 7 days after transfer into LPS challenged recipients.

(I) Differential *miR-146a** expression in CD14⁺(CD16⁻) and CD16⁺(CD14⁻) monocytes from three healthy donors (HD) ex vivo.

(J) Induction of *miR-146a** in CD14⁺(CD16⁻) monocytes 6 hr post-LPS challenge (same donors as in I; $n = 3$ technical replicates per group).

(K) Percent change of *Relb* mRNA expression in CD14⁺(CD16⁻) monocytes of HD5 6 hr post-LPS challenge in presence of a scrambled or *anti-miR-146a* LNA ($n = 3$).

(L) Immunofluorescence staining of *Relb* protein in CD14⁺(CD16⁻) monocytes analyzed ex vivo (ø) or treated as in (K) Images are representative of $n = 11$ –19 cells analyzed per condition. Scale bar represents 10 μ m. Quantification shows cytoplasmic versus nuclear fluorescence signal ratios. Data are presented as mean \pm SEM (* $p < 0.05$, ** $p < 0.001$, *** $p < 0.0001$, Student's *t* test).

See also Figure S4.

monocytes (Figure S4L). These data are in line with previous findings that CD14^{lo}CD16⁺ monocytes resemble Ly6C^{lo} cells and respond less well to LPS in comparison to CD14⁺CD16⁺ and CD14⁺CD16⁻ monocytes, which resemble mouse Ly6C^{hi} monocytes (Cros et al., 2010). Furthermore, human CD14⁺ monocytes challenged with LPS decreased *Relb* mRNA levels (Figure 4K), although treatment with a LNA to suppress *miR-146a** induction (Figure S4M) was sufficient to prevent *Relb* downregulation (Figures 4K and 4L).

DISCUSSION

This study provides functional evidence that *miR-146a* and *Relb* differentially regulate monocyte subsets. Following inflammatory challenge, modulation of *miR-146a* expression tunes the amplitude of the Ly6C^{hi}—but not the Ly6C^{lo}—monocyte response: premature *miR-146a* induction aborts Ly6C^{hi} cell amplification whereas lack of *miR-146a* induction leads to expansion and increased recruitment of these cells. *miR-146a* in monocytes targets *Relb*, which expression levels tune the amplitude of Ly6C^{hi} monocyte responses.

Recent work has identified *miR-146a* as a negative regulator of the canonical NF- κ B inflammatory cascade by targeting *Traf6* and *Irak1/2* (O'Connell et al., 2010) and as a tumor suppressor gene by decreasing transcription of NF- κ B-targeted genes (Boldin et al., 2011; Zhao et al., 2011). The present study extends the role of *miR-146a* to the control of *Relb*, which is mostly implicated in the noncanonical NF- κ B pathway (Vallabhapuram and Karin, 2009). *Relb* has sizable effects on mononuclear phagocytes as it controls dendritic cell development in humans (Platzer et al., 2004) and mice (Burkly et al., 1995; Cejas et al., 2005; Wu et al., 1998), and the generation of monocyte-derived osteoclasts (Vaira et al., 2008). In accordance with the present study, the noncanonical NF- κ B pathway activator CD40L also controls Ly6C^{hi} monocyte expansion (Lutgens et al., 2010). Of note, *miR-146a* can regulate proinflammatory gene expression by controlling *Relb*-dependent reversible chromatin remodeling (El Gazzar et al., 2011).

Ly6C^{lo} monocytes constitutively express *miR-146a* in accordance with their noninflammatory properties (Nahrendorf et al., 2007; Auffray et al., 2009). Nevertheless, *miR-146a*^{-/-} Ly6C^{lo} cells did not mount an inflammatory response that was notably higher than their wild-type counterparts. It is possible that *miR-146a* does not play a significant role in Ly6C^{lo} cells; yet, other regulatory mechanisms may keep Ly6C^{lo} cells in check in absence of *miR-146a*. The study of Ly6C^{lo} cells that bear defects in several candidate factors (e.g., *miR-146a* and other miRNAs) may serve to address this question. Either way, the present findings indicate that selective targeting of the *miR-146a* pathway should control Ly6C^{hi} monocyte responses while preserving Ly6C^{lo} cells.

Previous work has identified that *miR-146a*^{-/-} macrophages produce higher levels of inflammatory cytokines than their wild-type counterparts (Boldin et al., 2011); however, we could not recapitulate these findings in *miR-146a*^{-/-} monocytes. Challenged *miR-146a*^{-/-} and wild-type Ly6C^{hi} monocytes may produce the same amount of cytokines on a per-cell basis because *miR-146a* upregulation is induced after the initial burst of inflam-

matory cytokine production (4–24 hr versus 0–8 hr, respectively). Yet, *miR-146a*^{-/-} Ly6C^{hi} monocytes will contribute more cytokine production at target sites not only because more of these cells are recruited but also because they can give rise locally to *miR-146a*^{-/-} macrophages, which exhibit heightened inflammatory functions.

The findings presented here place *miR-146a* and *Relb* as key regulators of monocyte subset population dynamics. *miR-146a* and *Relb* preferentially control Ly6C^{hi} monocytes, which are cells that selectively expand in many chronic inflammatory conditions. Targeting of *miR-146a* or *Relb* may serve to suppress adverse inflammatory Ly6C^{hi} monocyte responses while sparing Ly6C^{lo} monocyte activity.

EXPERIMENTAL PROCEDURES

Mouse and Human Samples

The studies used 6- to 12-week-old mice. The institutional subcommittee on research animal care at Massachusetts General Hospital approved the animal studies. Human blood was obtained from healthy volunteers and collected in heparinized collection tubes in accordance to a protocol approved by the Committee on microbiological safety at Harvard Medical School.

Monoclonal Antibodies, Flow Cytometry, and Cell Sorting

Cell staining and cell sorting was performed as described in Supplemental Experimental Procedures.

Gene Expression Arrays and analysis

Gene expression studies were performed in accordance to MIAME guidelines and are described in Supplemental Experimental Procedures.

In Vivo Challenges

LPS from *Escherichia coli* (serotype O55:B5, Sigma) was given at 0.4 mg/kg in PBS daily i.p. for 4 days (or 7 days when indicated). *Lm* bacteria (strain EGDe, ATCC) were expanded in Brain Heart Broth (Fluka) and given intravenously at 3×10^3 colony forming units. Thioglycollate was given i.p. as a 4% solution in 1 ml RMPI.

In Vitro Challenges

Isolated cells ($5\text{--}6 \times 10^4$) were plated in complete medium (RPMI, Cellgro Mediatech), 10% FCS (Stem Cell Technologies), 100 U/ml Pen/strep, and 2 mM L-Glu (both Cellgro Mediatech) in round bottom 96-well plates. Stimulations included LPS (100 ng/ml, Sigma), rmTNF α (50 ng/ml, Peprotech), and HKLM (5×10^8 heat-killed *Lm*/ml, Invivo Gen). Luminex cytokine assays (R&D Biosciences) were analyzed on a Luminex FlexMap 3D (Agilent) instrument.

Statistical Analysis

Results were analyzed with Prism 4.0 (GraphPad). P-values were determined using Student's *t* tests. A *p* value < 0.05 was taken as statistically significant and higher significance is indicated in the figure legends. All graphs show mean \pm SEM.

ACCESSION NUMBERS

The microarray data generated in this study have been deposited to the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/gds>) under accession number GSE32392.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures and four figures and can be found with this article online at doi:10.1016/j.celrep.2012.02.009.

LICENSING INFORMATION

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License (CC-BY-NC-ND; <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>).

ACKNOWLEDGMENTS

The authors thank Mike Waring, Andrew Cosgrove, and Adam Chicoine (Ragon Institute of MGH, MIT, and Harvard) for cell sorting; Borja Saez (Harvard Medical School), Patrick Stern, and David Feldser (MIT) for help with retroviral gene transfer. Charles Vanderburg and Anna Krichevsky (Harvard Medical School) for help with analytical RNA techniques; and Yoshiko Iwamoto and Joshua Dunham (MGH Center for Systems Biology) for help with immunofluorescence staining and imaging. M.E. is part of the International PhD program "Cancer and Immunology" at the University of Lausanne, Switzerland and was supported by the American Association for Cancer Research Centennial Predoctoral Fellowship and the Boehringer Ingelheim Fonds. This work was supported in part by National Institutes of Health grants NIH-R01 AI084880 (to M.J.P.) and P30 DK043351 (to M.J.P. and R.X.). D.B. is a director and chairman of the scientific advisory board of Regulus Therapeutics, a biotech company developing miRNA-based drugs.

Received: October 12, 2011

Revised: February 14, 2012

Accepted: February 24, 2012

Published online: April 5, 2012

REFERENCES

- Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., Cumano, A., Lauvau, G., and Geissmann, F. (2007). Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. *Science* 317, 666–670.
- Auffray, C., Sieweke, M.H., and Geissmann, F. (2009). Blood monocytes: development, heterogeneity, and relationship with dendritic cells. *Annu. Rev. Immunol.* 27, 669–692.
- Boldin, M.P., Taganov, K.D., Rao, D.S., Yang, L., Zhao, J.L., Kalwani, M., Garcia-Flores, Y., Luong, M., Devrekanli, A., Xu, J., et al. (2011). miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. *J. Exp. Med.* 208, 1189–1201.
- Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L.A., Olson, D., Tizard, R., Cate, R., and Lo, D. (1995). Expression of relB is required for the development of thymic medulla and dendritic cells. *Nature* 373, 531–536.
- Cejas, P.J., Carlson, L.M., Kolonias, D., Zhang, J., Lindner, I., Billadeau, D.D., Boise, L.H., and Lee, K.P. (2005). Regulation of RelB expression during the initiation of dendritic cell differentiation. *Mol. Cell. Biol.* 25, 7900–7916.
- Cheong, C., Matos, I., Choi, J.H., Dandamudi, D.B., Shrestha, E., Longhi, M.P., Jeffrey, K.L., Anthony, R.M., Kluger, C., Nchinda, G., et al. (2010). Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. *Cell* 143, 416–429.
- Cros, J., Cagnard, N., Woollard, K., Patey, N., Zhang, S.Y., Senechal, B., Puel, A., Biswas, S.K., Moshous, D., Picard, C., et al. (2010). Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. *Immunity* 33, 375–386.
- El Gazzar, M., Church, A., Liu, T., and McCall, C.E. (2011). MicroRNA-146a regulates both transcription silencing and translation disruption of TNF- α during TLR4-induced gene reprogramming. *J. Leukoc. Biol.* 90, 509–519.
- Farh, K.K., Grimson, A., Jan, C., Lewis, B.P., Johnston, W.K., Lim, L.P., Burge, C.B., and Bartel, D.P. (2005). The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. *Science* 310, 1817–1821.
- Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., and Ley, K. (2010). Development of monocytes, macrophages, and dendritic cells. *Science* 327, 656–661.
- Lutgens, E., Lievens, D., Beckers, L., Wijnands, E., Soehnlein, O., Zernecke, A., Seijkens, T., Engel, D., Cleutjens, J., Keller, A.M., et al. (2010). Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. *J. Exp. Med.* 207, 391–404.
- Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., and Van Ginderachter, J.A. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Res.* 70, 5728–5739.
- Nahid, M.A., Pauley, K.M., Satoh, M., and Chan, E.K. (2009). miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. *J. Biol. Chem.* 284, 34590–34599.
- Nahrendorf, M., Swirski, F.K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.L., Libby, P., Weissleder, R., and Pittet, M.J. (2007). The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. *J. Exp. Med.* 204, 3037–3047.
- O'Connell, R.M., Rao, D.S., Chaudhuri, A.A., and Baltimore, D. (2010). Physiological and pathological roles for microRNAs in the immune system. *Nat. Rev. Immunol.* 10, 111–122.
- Platzer, B., Jörgl, A., Taschner, S., Höcher, B., and Strobl, H. (2004). RelB regulates human dendritic cell subset development by promoting monocyte intermediates. *Blood* 104, 3655–3663.
- Qian, B.Z., and Pollard, J.W. (2010). Macrophage diversity enhances tumor progression and metastasis. *Cell* 141, 39–51.
- Shi, C., and Pamer, E.G. (2011). Monocyte recruitment during infection and inflammation. *Nat. Rev. Immunol.* 11, 762–774.
- Swirski, F.K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.L., Kohler, R.H., Chudnovskiy, A., Waterman, P., et al. (2009). Identification of splenic reservoir monocytes and their deployment to inflammatory sites. *Science* 325, 612–616.
- Swirski, F.K., Libby, P., Aikawa, E., Alcaide, P., Luscinskas, F.W., Weissleder, R., and Pittet, M.J. (2007). Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atherosclerotic lesions. *J. Clin. Invest.* 117, 195–205.
- Tacke, F., Alvarez, D., Kaplan, T.J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., et al. (2007). Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. *J. Clin. Invest.* 117, 185–194.
- Taganov, K.D., Boldin, M.P., Chang, K.J., and Baltimore, D. (2006). NF- κ B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc. Natl. Acad. Sci. USA* 103, 12481–12486.
- Vaira, S., Johnson, T., Hirbe, A.C., Alhawagri, M., Anwisy, I., Sammut, B., O'Neal, J., Zou, W., Weilbaecher, K.N., Faccio, R., and Novack, D.V. (2008). RelB is the NF- κ B subunit downstream of NIK responsible for osteoclast differentiation. *Proc. Natl. Acad. Sci. USA* 105, 3897–3902.
- Vallabhapurapu, S., and Karin, M. (2009). Regulation and function of NF- κ B transcription factors in the immune system. *Annu. Rev. Immunol.* 27, 693–733.
- Varol, C., Landsman, L., Fogg, D.K., Greenshtein, L., Gildor, B., Margalit, R., Kalchenko, V., Geissmann, F., and Jung, S. (2007). Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. *J. Exp. Med.* 204, 171–180.
- Wu, L., D'Amico, A., Winkel, K.D., Suter, M., Lo, D., and Shortman, K. (1998). RelB is essential for the development of myeloid-related CD8 α -dendritic cells but not of lymphoid-related CD8 α + dendritic cells. *Immunity* 9, 839–847.
- Zhao, J.L., Rao, D.S., Boldin, M.P., Taganov, K.D., O'Connell, R.M., and Baltimore, D. (2011). NF- κ B dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. *Proc. Natl. Acad. Sci. USA* 108, 9184–9189.
- Ziegler-Heitbrock, L. (2007). The CD14+ CD16+ blood monocytes: their role in infection and inflammation. *J. Leukoc. Biol.* 81, 584–592.